Breast Cancer Watch Time: 36 mins

touchEXPERT OPINIONS From publication to practice: How trial data translate to clinical use of CDK4/6 Inhibitors in patients with HR+/HER2- advanced breast cancer

Watch leading international experts in breast cancer discuss the latest findings relating to overall survival (OS) with CDK4/6 inhibitors in HR+/ HER2- advanced breast cancer and address the recommendations and practical issues relating to these treatments in daily practice.

Now Playing:
Up Next:
 
Prof. Dr Sherko Kümmel
Kliniken Essen-Mitte, Essen, Germany
What are the implications of the overall survival data for CDK4/6 inhibitors for daily practice?

Prof. Dr. Sherko Kümmel discusses the implications of the latest data for overall survival (OS) with CDK4/6 inhibitors and how these translate into decision-making regarding treatment for patients with HR+/HER2- advanced breast cancer in daily clinical practice.

1/3 Next Interview
Leave Feedback
Interview Questions
  • How would you define a clinically meaningful response in patients with HR+/HER2- advanced breast cancer?
  • What were the OS outcomes across the PALOMA-3, MONALEESA-3 and -7, and MONARCH 2 trials?
  • What could explain the differences between the OS reported from the Phase III trials?
  • Taking into consideration the latest data, which patients should receive a CDK4/6 inhibitor and when?
About Prof. Dr Sherko Kümmel

Prof. Dr. Sherko Kümmel is the Clinical Director and Lead in Breast Cancer Research at Kliniken Essen-Mitte in Germany. He is a member of several international organizations, including the European Society of Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO), and has participated as a key member in several global scientific initiatives to improve the lives of patients with breast cancer. He has acted as principal investigator for several international trials and has been a member of several steering committees. He has published over 200 papers in peer-reviewed journals, and has lectured and presented extensively at international meetings on breast cancer.

Disclosures: Consulting or advisory role for Amgen, AstraZeneca, Celgene, Daichii Sankyo, Lilly, Genomic Health, MSD, Novartis, Pfizer, pfm medical, Puma Biotechnology, Roche/Genentech and Somatex. Travel, accommodation and expenses from Daiichi Sankyo, Roche and Sonoscape.

 
Dr Sara Hurvitz
University of California, Los Angeles (UCLA), Los Angeles, USA
What factors can help determine which CDK4/6 inhibitor to prescribe?

Dr Sara Hurvitz outlines some of the key differences between the available CDK4/6 inhibitors that could influence drug choice for individual patients and discusses how this information might be applied in clinical practice.

2/3 Next Interview
Leave Feedback
Interview Questions
  • How do you think the availability of overall survival data for CDK4/6 inhibitors influences the choice of therapy in HR+/HER2- advanced breast cancer?
  • How do patient and disease profiles affect treatment decisions in HR+/HER2- advanced breast cancer?
  • How do differences in the safety profiles for the different CDK4/6 inhibitors influence treatment choice?
  • What are the dosing considerations for CDK4/6 inhibitors in patients with HR+/HER2- advanced breast cancer?
About Dr Sara Hurvitz

Dr Sara Hurvitz is Associate Professor of Medicine at the University of California, Los Angeles (UCLA), Co-Director of the Santa Monica-UCLA Outpatient Oncology Practice, Medical Director of the Clinical Research Unit of the Jonsson Comprehensive Cancer Center at UCLA, and Director of Breast Oncology. She is a member of the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR) and is a Fellow of the American College of Physicians (ACP). Dr Hurvitz has won numerous awards, including the Marni Levine Memorial Breast Cancer Research Award 2008 through 2015. She has an active clinical practice specializing in the treatment of women with breast cancer and she is involved in designing, implementing and leading multiple national and international clinical trials testing new targeted therapies. She also leads the preclinical evaluation of novel breast cancer targets in the Translation Oncology Research Laboratory at UCLA.

Disclosures: Contracted research for and medical writing assistance from Ambrx, Amgen, Arvinas, Bayer, Daiichi-Sankyo, Dignitana, Eli Lilly, Genentech/Roche, GlaxoSmithKline, Immunomedics, Macrogenics, Novartis, OBI Pharma, Pfizer, Pieris, PUMA, Radius, Sanofi and Seattle Genetics.

 
Prof. Dr. MED. Peter Fasching
Comprehensive Cancer Center Erlangen-EMN, Nuremberg, Germany
What is the optimal approach to managing a patient on a CDK4/6 inhibitor?

Prof. Dr. med. Peter Fasching discusses the optimal management of patients who are taking a CDK4/6 inhibitor for HR+/HER2- advanced breast cancer, including approaches to monitoring quality of life and managing adverse events.

3/3 Leave Feedback
Leave Feedback
Interview Questions
  • How important is quality of life when treating women with HR+/HER2- advanced breast cancer and how can it be assessed?
  • What impact on quality of life might be expected for patients with HR+/HER2- advanced breast cancer treated with a CDK4/6 inhibitor?
  • Which patient-reported outcomes have been evaluated for CDK4/6 inhibitors in HR+/HER2- advanced breast cancer?
  • What are the key considerations when supporting adherence to treatment with CDK4/6 inhibitors?
About Prof. Dr. MED. Peter Fasching

Prof. Dr. med. Peter Fasching is a Women’s Cancer Specialist at the Comprehensive Cancer Center Erlangen-EMN, Nuremberg, Germany. He is also Lead of the Clinical Trials Unit for Womens’ Cancers and Lead of the Breast Cancer Group at the centre, and Professor of Gynecology and Obstetrics in the Department of Gynecology/Obstetrics at University Hospital Erlangen.

Prof. Dr. med. Fasching’s main research focus is on clinical Phase I-IV studies, multiomics biobanking and the identification of novel targets for cancer therapies integrating multiomics and big data approaches. He has more than 520 PubMed-listed publications and in 2017 was the recipient of the Florence Nightingale Award of the German Society of Breast Diseases.

Disclosures: Personal fees from AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Lilly, Macrogenics, Merck Sharp & Dohme, Novartis, Pfizer, Puma and Roche. Grants from BionTech, Cepheid and Novartis.

Leave Feedback
Overview & Learning Objectives
Overview

Watch leading international experts in breast cancer discuss the latest findings relating to overall survival (OS) with CDK4/6 inhibitors in HR+/ HER2- advanced breast cancer and address the recommendations and practical issues relating to these treatments in daily practice.

Prof. Dr. Sherko Kümmel, Kliniken Essen-Mitte, Germany, discusses the implications of the OS data for CDK4/6 inhibitors reported in clinical trials for daily practice.

Dr Sara Hurvitz, University of California, Los Angeles (UCLA), USA, addresses the factors that can help determine which CDK4/6 inhibitor to prescribe for which patient.

Prof. Dr. med. Peter Fasching, Comprehensive Cancer Center Erlangen-EMN, Germany, provides insights into the quality of life with CDK4/6 inhibitors and approaches to optimizing adherence and managing adverse events in clinical practice.

This activity is intended for oncologists and oncology nurses involved in the treatment of patients with breast cancer.

Learning Objectives

After accessing the touchEXPERT OPINIONS activity, the audience should be better able to:

  • Identify patients with HR+/HER2- advanced breast cancer suitable for treatment with a CDK4/6 inhibitor
  • Understand the key differences between the CDK4/6 inhibitors and how these might influence drug choice for individual patients
  • Apply knowledge of the CDK4/6 inhibitor’s dosing, safety profile and monitoring requirements to optimize patient management

This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.

Accept Decline
Feedback Close
Feedback

Please provide feedback for this touchEXPERT OPINIONS on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72